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Performance of the OraQuick HCV Rapid Antibody Test for
Screening Exposed Patients in a Hepatitis C Outbreak Investigation
Fengxiang Gao,a Elizabeth A. Talbot,b,c Carol H. Loring,a Jill J. Power,a Jodie Dionne-Odom,b,c Sharon Alroy-Preis,b Patricia Jackson,b
Christine L. Beana
Public Health Laboratories, Division of Public Health Services, New Hampshire Department of Health and Human Services, Concord,a Division of Public Health Services,
New Hampshire Department of Health and Human Services, Concord,b and Geisel School of Medicine at Dartmouth, Hanover,c New Hampshire, USA

During a nosocomial hepatitis C outbreak, emergency public clinics employed the OraQuick HCV rapid antibody test on site,
and all results were verified by a standard enzyme immunoassay (EIA). Of 1,157 persons, 1,149 (99.3%) exhibited concordant
results between the two tests (16 positive, 1,133 negative). The sensitivity, specificity, positive predictive value, and negative predictive value were 94.1%, 99.5%, 72.7%, and 99.9%, respectively. OraQuick performed well as a screening test during an outbreak investigation and could be integrated into future hepatitis C virus (HCV) outbreak testing algorithms.

C

linical signs and symptoms of hepatitis C virus (HCV) infection are generally nonspecific, and many patients with acute
or chronic infection are asymptomatic. As a result, laboratory testing for evidence of HCV infection is required for diagnosis. Because of its high sensitivity, ease of automation, and relatively low
cost, enzyme immunoassay (EIA) for the detection of the IgG class
of antibodies to HCV (IgG anti-HCV) is the most commonly used
approach to HCV infection screening. Generally, EIA requires a
subsequent patient encounter to provide results. This delay can
lead to patient anxiety or loss to follow-up.
Recently, rapid HCV antibody tests have been developed and
their performance has been evaluated (1, 2). The OraQuick HCV
rapid antibody test (OraQuick), manufactured by OraSure Technologies, Inc., is the first to gain approval by the Food and Drug
Administration (FDA) (3) and a Clinical Laboratory Improvement Amendments (CLIA) waiver (4) for qualitative detection of
HCV antibodies in finger stick or venipuncture whole blood.
OraQuick is a single-use lateral-flow indirect immunoassay intended for use in symptomatic or high-risk asymptomatic patients. Results can be obtained at the point of care in 20 to 40 min.
In earlier evaluations of symptomatic or high-risk asymptomatic
patients, OraQuick demonstrated high sensitivity (97.8 to 100%)
and specificity (99.5 to 100%) (1, 5, 6). Few studies have evaluated
the performance of the test in a low-risk population. One (7)
conducted by OraSure Technologies and collaborators examined
450 low-risk subjects and demonstrated high sensitivity (100%)
and specificity (100%) of OraQuick with both finger stick blood
and venous whole blood. No performance data for OraQuick have
been reported for screening a large population of patients at mixed
risk for HCV infection, such as during an outbreak investigation.
On 25 May 2012, the New Hampshire Division of Public
Health Services (NH DPHS) confirmed an HCV outbreak at a
local hospital cardiac catheterization laboratory (CCL) (8). Epidemiologic and laboratory data strongly suggested that their
source was an infected health care worker (HCW) who was diverting narcotics (8). The NH DPHS recommended HCV testing for
all patients who received care in all at-risk settings during the
period of this HCW’s employment at the local hospital. Due to the
large number of patients indicated for testing, and intense community concern, NH DPHS organized eight emergency public
health clinics for HCV testing in two stages: OraQuick on site,
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followed by EIA and any necessary supplemental testing performed at the New Hampshire Public Health Laboratories (NH
PHL).
NH DPHS notified all patients who were indicated for HCV
testing of the eight scheduled public clinics through direct phone
calls and letters as well as the local media. At the clinics, two serum
separator tubes (SSTs) and one lavender (anticoagulant) tube
from each eligible patient were obtained. The lavender tube was
for the OraQuick HCV rapid test at the public health clinics, and
the two SSTs were for EIA and supplemental testing at the NH
PHL. Patients were counseled and offered their OraQuick test
result on site by trained counselors. Patients who elected not to
receive their result on site were called and/or mailed their results.
Laboratorians from the NH PHL and Laboratory Response
Network facilities were trained on the OraQuick HCV rapid antibody test and proficiency tested by OraSure Technologies, Inc.,
technical representatives. Testing was performed on venipuncture
whole blood in accordance with the manufacturer’s instructions
(9). Any specimen that tested positive or invalid was retested on
site by a second tester who was blinded to the original result and
was unaware that the test was a repeat test. Once confirmed, a
result was finalized and provided to the patient. All specimens
with positive or invalid OraQuick test results were also repeat
tested at the NH PHL.
Serum specimens were transported from the clinic settings to the
NH PHL within 6 h of collection using coolers with cold packs. Upon
receipt, the SSTs were centrifuged and tested for anti-HCV antibodies
by use of the Ortho HCV version 3.0 EIA (Ortho Clinical Diagnostics,
Rochester, NY) (10) with the ETI-Max 3000 automated EIA analyzer
(DiaSorin). The remaining serum specimens were frozen at ⫺70°C
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TABLE 1 Summary of test results of OraQuick anti-HCV rapid test in
comparison with Ortho HCV version 3.0 EIA
No. of patients with indicated EIA result
OraQuick result

Positive

Negative

Total

Positive
Negative
Invalid

16
1
0

6
1,133
1

22
1,134
1

Total

17

1,140

1,157

and used for supplemental testing, if necessary. Final results were
obtained within 48 h of specimen collection.
Specimens which yielded discordant results between OraQuick
and EIA were frozen at ⫺70°C and sent to the laboratory at the
Division of Viral Hepatitis of the Centers for Disease Control and
Prevention (CDC) to be tested for anti-HCV using the Ortho
Vitros immunodiagnostics anti-HCV chemiluminescence immunoassay (CIA) (Ortho Clinical Diagnostics, Rochester, NY). The
CIA was performed according to the manufacturer’s instructions
(11). Specimens which tested positive by either OraQuick or EIA
were tested for HCV RNA by use of the Cobas Amplicor HCV test,
v2.0 (Roche Molecular Diagnostics, Almere, Netherlands) (12).
Of 1,157 patients presenting to the eight public clinics, 714
(61.7%) were female and 443 (38.3%) were male. Their median
age was 53 years (range, 15 to 95 years). After OraQuick testing, 22
(1.9%) were found to be positive, 1 (0.1%) had an invalid result,
and 1,134 (98.0%) were negative (Table 1). Repeat OraQuick testing on specimens yielding positive or invalid results was 100%
reproducible both on site and at the NH PHL.
Six of the 22 specimens (27%) which were positive by
OraQuick were negative by EIA. One specimen with an invalid
OraQuick result tested negative by EIA. One of the 1,134 specimens (0.1%) which tested negative by OraQuick tested positive by
EIA. Excluding the invalid result, the sensitivity and specificity of
OraQuick compared with EIA were 94.4% and 99.4%, respectively. The negative predictive value (NPV) and positive predictive
value (PPV) of OraQuick were 99.9% and 72.7%, respectively.
The seven specimens with discordant results underwent CIA
testing at the CDC (Table 2). Of the six that were OraQuick positive and EIA negative, five tested negative and one tested positive
by CIA, suggesting five false-positive results by OraQuick and one
false-negative result by EIA when agreement of two tests out of
three (OraQuick, EIA, and CIA) was used as the determinant result. Of note, the specimen that tested positive by CIA (specimen
2) gave a CIA signal-to-cutoff ratio of 1.18, just above the cutoff of
1.00. Discordant specimen 7, which tested negative by OraQuick
and positive by EIA, was positive by CIA, suggesting one falsenegative result by OraQuick. All seven specimens tested negative
for HCV RNA by reverse transcription (RT)-PCR.
This is the first report of the OraQuick HCV rapid antibody
test for the detection of HCV antibodies in a large population with
potential exposure to nosocomial HCV infection. Compared with
EIA, we confirm that the OraQuick assay demonstrated high specificity (99.5%), which is similar to the findings of other reports (1,
5, 6). OraQuick also displayed a high NPV (99.9%), which is a
critical characteristic for a screening test, especially in the setting
of mass testing related to an outbreak, because it is critical to
provide the patient reassurance regarding the absence of disease
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TABLE 2 Summary of test results for patients with discordant results
between OraQuick and EIAa
Specimen
identification
no.

OraQuick

EIA (SCR)

CIA (SCR)

HCV RNA

1
2
3
4
5
6
7

Positive
Positive
Positive
Positive
Positive
Positive
Negative

Negative (0.007)
Negative (0.31)
Negative (0.016)
Negative (0.013)
Negative (0.043)
Negative (0.011)
Positive (5.123)

Negative (0.02)
Positive (1.18)
Negative (0.02)
Negative (0.02)
Negative (0.43)
Negative (0.01)
Positive (12.9)

Negative
Negative
Negative
Negative
Negative
Negative
Negative

a
SCR, signal-to-cutoff ratio. Specimens were considered as reactive for antibody to
HCV if the SCR was ⱖ1.0 in both EIA and chemiluminescence immunoassay (CIA).
The HCV RNA test was performed using the Cobas Amplicor HCV test, v2.0.

with a high degree of confidence. The sensitivity (94.1%) in our
study was slightly lower than previously reported (97.8% to
100%) (1, 2), likely an artifact of a relatively small sample size. We
consider the modest PPV (72%) to not be a significant limitation
for OraQuick as a screening test, because all positive results should
be confirmed by additional testing.
Nosocomial HCV outbreaks have been increasingly identified
as a source of HCV transmission and usually require screening of
large populations. Between 2008 and 2012, 16 hepatitis C outbreaks were reported in the United States and more than 90,000
at-risk persons were advised to undergo HCV screening (13).
Screening of large populations is challenging, and the use of a
rapid test can greatly aid testing efforts.
We demonstrate that OraQuick can be used in an outbreak
setting to allow rapid screening of a large number of patients. This
can identify HCV-infected patients who may be informed of their
status and offered counseling to prevent further spread of the
virus. In addition, timely identification or exclusion of HCV infection reduces anxiety and frustration among those potentially
exposed.
In this study, CIA results were consistent with the EIA results
for all but one specimen. The single patient whose specimen tested
positive by OraQuick, negative by EIA, and positive by CIA may
be explained by early infection/seroconversion or may be a biological false positive due to an unidentified interfering substance.
Testing the patient at a later date would be useful to resolve the
testing discrepancy in this single patient.
In a previous study (1), false results with OraQuick ranging
from 0.65% to 1.31% were reported and the association between
gender and false results was determined. In the current report, we
found six specimens (0.52%) displaying false results and five of
them were from females. This is consistent with the finding in the
previous study that gender was associated with false rapid antiHCV results of OraQuick testing. It is unclear why a higher occurrence of false rapid anti-HCV results is observed in females, and
more studies are needed.
In this public health response, OraQuick was performed in
nontraditional emergency public health clinics set up in nonmedical community settings (e.g., local school gymnasiums and cafeterias). The settings exhibited different ambient conditions, such
as non-air-conditioned space in the summer and less-than-ideal
lighting for reading the results. In spite of these limitations, there
was only one invalid result, and repeat testing under controlled
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conditions at the NH PHL documented perfect reproducibility.
One limitation to our discordant analysis is that the recombinant
immunoblot assay (RIBA) became unavailable in March 2012.
RIBA had previously been considered a confirmatory test for positive IgG anti-HCV EIA or CIA test results. We were unable to
confirm the anti-HCV results for those specimens with discrepant
results between OraQuick and the EIA due to the manufacturer’s
discontinuation of RIBA.
Recently, the CDC has recommended widespread screening of
“baby boomers” (persons born during 1945 and 1965) without
prior determination of HCV risk because of the high prevalence of
HCV infection and related disease (14). To help health care providers and public health professionals implement this recommendation, the CDC proposed a laboratory testing algorithm for identifying current HCV infection (15). This testing algorithm
includes OraQuick as a screening test.
Our findings demonstrate that OraQuick is a robust and reliable field tool to detect HCV infection in the setting of mass testing. Supplemental testing using an RT-PCR assay and/or immunoassays should be performed on any specimen exhibiting a
positive result.
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